29 Lesion detection by [89Zr]Zr-DFO-girentuximab and [18F]FDG PET/CT in mccRCC patients Table 1. Patient demographics and clinical characteristics. (continued) Parameter Patients (n =42) Location of first metastases a Lung b 22 (52%) Adrenal gland 4 (10%) Lymph node 9 (21%) Bone 2 (5%) Kidney 2 (5%) Other c 3 (7%) Time from diagnosis to first metastases (median 0.7; range 0-15 months) <1 year 23 (55%) ≥1 year 19 (45%) IMDC risk factors 0 (favorable) 14 (33%) 1 (intermediate) 13 (31%) 2 (intermediate) 15 (36%) * 57% presented with synchronous metastases ** 5 patients had lung-only disease (based on CT only). *** 2 patient presented with soft tissue metastases,1 patient with multiple involved organ sites. Figure 1. On the left are transversal sections of one patient of CT, [89Zr]Zr-DFO-girentuximab and [18F]FDG-PET/CT. The red circle represents an adrenal gland lesion in a patient as visualized by CT (A), [89Zr]Zr-DFO-girentuximab (B) and [18F]FDG-PET/CT (C), respectively. On the right, MIP images of [89Zr]Zr-DFO-girentuximab (D) and [18F]FDG-PET/CT (E) are presented. 2
RkJQdWJsaXNoZXIy MTk4NDMw